ClinicalTrials.Veeva

Menu

Neutrophil Side Fluorescent Light (NEU-SFL) in COVID-19 Patients (NEU-COVID)

C

Centre Hospitalier Universitaire de Nīmes

Status

Completed

Conditions

COVID-19

Study type

Observational

Funder types

Other

Identifiers

NCT05413824
Local/2022/SB-01

Details and patient eligibility

About

Recently, a study showed that markers of neutrophil extracellular traps formation, a mechanism corresponding to neutrophil activation, were increased in patients who died of COVID 19 compared with survivors.

The investigators propose to analyze the NEU-SFL parameter, obtained automatically on the Sysmex™ blood count machine (Sysmex Corporation, Kobe, Japan) and which is considered as a reflect of neutrophil extracellular traps formation, in these two groups of patients. The aim was to evaluate whether this parameter could be used to predict the risk of death related to COVID 19.

Enrollment

2,233 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Hospitalization for COVID 19 in 2021

Exclusion criteria

  • Patients who refused the use of their data

Trial design

2,233 participants in 2 patient groups

COVID-19 survivors
Description:
Patients hospitalized at Nimes university hospital in 2021 for COVID-19 who survived.
COVID-19 Deceased
Description:
Patients hospitalized at Nimes university hospital in 2021 for COVID-19 who died.

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems